PL-8177

April 10, 2019April 10, 2019

UC Candidate Therapy PL-8177 Shows Successful Delivery to Lower GI Tract

News

Use of an oral, delayed-release formulation of the ulcerative colitis treatment candidate PL-8177 led to targeted delivery to the lower gastrointestinal tract and was well-tolerated, according to top-line results of ... Read more

April 11, 2018April 11, 2018

Oral PL-8177 Reduces Gut Inflammation in Rat Model of IBD, New Results Show

News

Palatin Technologies‘, investigational PL-8177, taken orally, reached the large intestine and colon, resulting in significantly reduced inflammation and damage in a bowel inflammation rat model. The poster on the study, ... Read more

January 5, 2018

Palatin to Start Clinical Trials of Ulcerative Colitis Therapy After FDA Sign-off

News

Palatin Technologies plans to start clinical trials of its ulcerative colitis therapy PL-8177 in the next three months. The U.S. Food and Drug Administration’s decision to accept Palatin’s Investigational New Drug application for the treatment opened ... Read more